Olodanrigan

• Product Name Alternative:

  EMA401; PD-126055; (S)-EMA400

• UNSPSC Description:

  Olodanrigan (EMA401) is a highly selective, orally active, peripherally restricted angiotensin II type 2 receptor (AT2R) antagonist. It is under development as a neuropathic pain therapeutic agent. Olodanrigan (EMA401) analgesic action appears to involve inhibition of augmented AngII/AT2R induced p38 and p42/p44 MAPK activation, and hence inhibition of DRG neuron hyperexcitability and sprouting of DRG neurons[1][2][3][4].

• Target Antigen:

  Angiotensin Receptor

• Type:

  Reference compound

• Related Pathways:

  GPCR/G Protein

• Field of Research:

  Neurological Disease; Endocrinology; Cardiovascular Disease

• Assay Protocol:

  https://www.medchemexpress.com/EMA401.html

• Purity:

  98.55

• Solubility:

  DMSO : ≥ 34 mg/mL|H2O : < 0.1 mg/mL

• Smiles:

  O=C([C@H]1N(C(C(C2=CC=CC=C2)C3=CC=CC=C3)=O)CC4=C(C(OCC5=CC=CC=C5)=C(OC)C=C4)C1)O

• Molecular Weight:

  507.58

• References & Citations:

  [1]Anand U et al. Mechanisms underlying clinical efficacy of Angiotensin II type 2 receptor (AT2R) antagonist EMA401 in neuropathic pain: clinical tissue and in vitro studies. Mol Pain. 2015 Jun 26;11:38.|[2]Suguru Koyama,et al. An Electroencephalography Bioassay for Preclinical Testing of Analgesic Efficacy.|[3]Rice AS et al. EMA401, an orally administered highly selective angiotensin II type 2 receptor antagonist, as a novel treatment for postherpetic neuralgia: a randomised, double-blind, placebo-controlled phase 2 clinical trial. Lancet. 2014 May 10;383(9929):1637-47.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  Phase 2

• CAS Number:

  1316755-16-4